RxDoctor Payments Data

Monroe Benaim, MD

Ophthalmology · Jupiter, FLNPI 1568569523

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,128 of the $1,726 with a category attached, or 65.4%. Alcon accounts for 86.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $1,517 and has fallen 97.4% since, to $39 in 2025. That places this record below the midpoint for ophthalmology clinicians in FL, where the typical reported total is $1,824.

$1,726in general payments, 2019–2025

Across 13 payments — averaging $132.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Ivantis, Inc$99
  • Halozyme Inc$39
  • Johnson & Johnson Surgical Vision, Inc.$27
  • Harrow Eye, LLC$23
  • ANI Pharmaceuticals, Inc.$22
  • plus $19 from 1 others

What the payments were for

  • Travel & lodging$1,12865%
  • Food & beverage$59835%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,726 in reported general payments places this provider in the 45th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida →

Medicare billing

Part B allowed, 2024
$319,603
Medicare patients
930
Services billed
3,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine31$18,978
LumiganBimatoprost16$8,961
Tobramycin-DexamethasoneTobramycin/Dexamethasone113$6,567
SimbrinzaBrinzolamide/Brimonidine Tart24$5,391
CombiganBrimonidine Tartrate/Timolol19$5,070
Travoprost25$3,683
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$2,648
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha237$2,570
Latanoprost243$1,835
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat62$1,699
Brimonidine Tartrate51$1,578
TafluprostTafluprost/Pf11$1,478
Timolol Maleate79$584
ErythromycinErythromycin Base69$513
Prednisolone Acetate12$485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$1,497$5,39124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Jupiter

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →